William Quinn Sells 6,545 Shares of Bolt Biotherapeutics (NASDAQ:BOLT) Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) CEO William Quinn sold 6,545 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $3.32, for a total value of $21,729.40. Following the completion of the sale, the chief executive officer directly owned 34,516 shares of the company’s stock, valued at $114,593.12. The trade was a 15.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bolt Biotherapeutics Stock Up 0.8%

BOLT traded up $0.03 during mid-day trading on Monday, reaching $3.59. 22,454 shares of the stock were exchanged, compared to its average volume of 27,365. Bolt Biotherapeutics, Inc. has a 1 year low of $3.10 and a 1 year high of $7.20. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. The stock has a market capitalization of $6.93 million, a PE ratio of -0.22 and a beta of 1.09. The company has a 50 day moving average price of $3.84 and a two-hundred day moving average price of $4.29.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.50 million. As a group, research analysts anticipate that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nan Fung Group Holdings Ltd purchased a new stake in shares of Bolt Biotherapeutics during the 2nd quarter worth approximately $19,250. Renaissance Technologies LLC grew its holdings in Bolt Biotherapeutics by 40.3% during the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after purchasing an additional 22,200 shares during the period. Finally, T3 Companies LLC bought a new position in Bolt Biotherapeutics during the fourth quarter valued at $208,000. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on BOLT. Rodman & Renshaw began coverage on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.